Bristows successfully defends provisional measures application at the UPC Court of Appeal
We are proud to report our successful defence for SOPHiA GENETICS of a PI application brought by Guardant Health Inc in the UPC Court of...
A bitter pill: Court of Appeal restores CMA’s Phenytoin excessive pricing decision
On 19 June 2026, the Court of Appeal (CoA) issued its judgment in Pfizer/Flynn v CMA, drawing a line under the long-running UK...
Skinny labelling after Hikma v Amarin: active inducement in the US Supreme Court
On 4 June 2026, the US Supreme Court handed down its judgment in Hikma Pharmaceuticals v Amarin Pharma, finding that Amarin Pharma...
Life Sciences disputes: navigating causation and damages in an uncertain world
As part of London International Disputes Week 2026, Bristows and Oxera hosted a discussion on causation, counterfactuals and damages in...
UK venture capital: a market rebounding?
Despite a backdrop of persistent geopolitical uncertainty, the UK venture capital (VC) space has entered a period of renewed growth and...
As a free user, you can like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net